Stroke Proteomics: From Discovery to Diagnostic and Therapeutic Applications

被引:36
|
作者
Hochrainer, Karin [1 ]
Yang, Wei [2 ]
机构
[1] Weill Cornell Med, Feil Family Brain & Mind Res Inst, 407 East 61st St, New York, NY 10065 USA
[2] Duke Univ, Sch Med, Dept Anesthesiol, Ctr Perioperat Organ Protect, Durham, NC USA
基金
美国国家卫生研究院;
关键词
biomarkers; diagnosis; prognosis; proteomic; stroke; therapy; CEREBRAL-ARTERY OCCLUSION; ALPHA-II-SPECTRIN; PROTEIN-KINASE-C; ACUTE ISCHEMIC-STROKE; TERMINAL HYDROLASE-L1; INTERACTING PROTEINS; CARDIOVASCULAR RISK; HEMORRHAGIC STROKE; BINDING PROTEIN; BRAIN-DAMAGE;
D O I
10.1161/CIRCRESAHA.122.320110
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Stroke remains a leading cause of death and disability, with limited therapeutic options and suboptimal tools for diagnosis and prognosis. High throughput technologies such as proteomics generate large volumes of experimental data at once, thus providing an advanced opportunity to improve the status quo by facilitating identification of novel therapeutic targets and molecular biomarkers. Proteomics studies in animals are largely designed to decipher molecular pathways and targets altered in brain tissue after stroke, whereas studies in human patients primarily focus on biomarker discovery in biofluids and, more recently, in thrombi and extracellular vesicles. Here, we offer a comprehensive review of stroke proteomics studies conducted in both animal and human specimen and present our view on limitations, challenges, and future perspectives in the field. In addition, as a unique resource for the scientific community, we provide extensive lists of all proteins identified in proteomic studies as altered by stroke and perform postanalysis of animal data to reveal stroke-related cellular processes and pathways.
引用
收藏
页码:1145 / 1166
页数:22
相关论文
共 50 条
  • [41] Path from discovery to recovery: therapeutic and diagnostic advances in Alzheimer's dementia
    Aung M. Saw
    James Hrastelj
    Neil P. Robertson
    Journal of Neurology, 2023, 270 (8) : 4151 - 4153
  • [42] LClinical proteomics: Diagnostic applications of mass spectrometry.
    Liotta, L
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2003, 226 : U123 - U123
  • [43] Non-coding RNAs: Emerging from the discovery to therapeutic applications
    Baptista, B.
    Riscado, M.
    Queiroz, J. A.
    Pichon, C.
    Sousa, F.
    BIOCHEMICAL PHARMACOLOGY, 2021, 189
  • [44] Quantitative proteomics reveals novel therapeutic and diagnostic markers in hypertension
    Matafora, Vittoria
    Zagato, Laura
    Ferrandi, Mara
    Molinari, Isabella
    Zerbini, Gianpaolo
    Casamassima, Nunzia
    Lanzani, Chiara
    Carpini, Simona Delli
    Trepiccione, Francesco
    Manunta, Paolo
    Bachi, Angela
    Capasso, Giovambattista
    BBA CLINICAL, 2014, 2 : 79 - 87
  • [45] Proteomics Applications in Health: Biomarker and Drug Discovery and Food Industry
    Amiri-Dashatan, Nasrin
    Koushki, Mehdi
    Abbaszadeh, Hojjat-Allah
    Rostami-Nejad, Mohammad
    Rezaei-Tavirani, Mostafa
    IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH, 2018, 17 (04): : 1523 - 1536
  • [46] Activity-based proteomics: Applications for enzyme and inhibitor discovery
    Cravatt, Benjamin
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 248
  • [47] Proteomics applications in biomarker discovery and pathogenesis for abdominal aortic aneurysm
    Wu, Jianqiang
    Wang, Wei
    Chen, Zhaoran
    Xu, Fang
    Zheng, Yuehong
    EXPERT REVIEW OF PROTEOMICS, 2021, 18 (04) : 305 - 314
  • [48] Activity-based proteomics — applications for enzyme and inhibitor discovery
    Cravatt, Benjamin
    FASEB JOURNAL, 2014, 28 (01):
  • [49] Applications of high throughput thermodynamic methods in proteomics & drug discovery
    Salemme, FR
    BIOPHYSICAL JOURNAL, 2003, 84 (02) : 284A - 284A
  • [50] Activity- based proteomics - applications for enzyme and inhibitor discovery
    Cravatt, Benjamin F.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 248